Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Nov 15, 2018; 10(11): 421-430
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.421
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.421
Table 2 Treatment characteristics
| sFOLFIRINOX | mFOLFIRINOX | P value | |
| (n = 88) | (n = 42) | ||
| Number of cycles administered, median (range) | 9.5 (4-24) | 12 (4-32) | 0.421 |
| Treatment duration, d, median (range) | 126 (42-322) | 154 (42-434) | 0.595 |
| RDI to sFOLFIRINOX, %, median (range) | |||
| Oxaliplatin | 85.3 (56.3-100) | 75.0 (51.1-75.0) | < 0.0011 |
| Irinotecan | 85.0 (56.3-100) | 75.0 (51.1-75.0) | < 0.0011 |
| 5-FU (bolus) | 92.1 (21.4-100) | 75.0 (51.1-75.0) | < 0.0011 |
| 5-FU (infusion) | 94.1 (56.3-100) | 75.0 (51.1-75.0) | < 0.0011 |
| Patients with ≥ 1 dose reduction, n (%) | 62 (70.5) | 16 (38.1) | < 0.0011 |
| Cause of dose reduction (> 5%), n (%) | |||
| Neutropenia | 53 (60.2) | 9 (21.4) | < 0.0011 |
| Febrile neutropenia | 10 (11.4) | 4 (9.5) | 1.000 |
| Patients with ≥ 1 dose delay, n (%) | 55 (62.5) | 22 (52.4) | 0.272 |
| Cause of dose delay (> 5%), n (%) | |||
| Neutropenia | 16 (18.2) | 5 (11.9) | 0.363 |
| Febrile neutropenia | 16 (18.2) | 5 (11.9) | 0.363 |
| Fatigue | 7 (8.0) | 8 (19.0) | 0.081 |
| No. of G-CSF administered, median (range) | 3.5 (0-24) | 2 (0-12) | 0.0431 |
| Patients received G-CSF, n (%) | 72 (81.8) | 27 (64.3) | 0.0281 |
- Citation: Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430
- URL: https://www.wjgnet.com/1948-5204/full/v10/i11/421.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i11.421